# XOMA Royalty Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/XOMA Royalty Corp). ## Overview XOMA Royalty Corp is a U.S.-based biotech royalty aggregator that acquires economic rights to future milestone payments, royalties, and commercial payments from partnered therapeutic programs. Its portfolio spans legacy out-licensing agreements, purchased royalty interests, and other income streams tied to drug development and product sales across multiple clinical and commercial assets. ## Products & services • Royalty interests in partnered therapeutic candidates • Milestone payment rights from drug development programs • Commercial royalty streams on approved products • Out-licensing of legacy product candidates and technologies • Purchased receivables tied to biotech revenue streams - **Royalty and milestone interests** (60%) — Economic rights to future royalties, milestones, and commercial payments from partnered drug assets. - **Purchased receivables** (25%) — Income from acquired receivables linked to royalty-bearing product sales and milestone events. - **Licensing and collaboration revenue** (15%) — Upfront fees, annual license fees, and milestone payments from legacy out-licensing agreements. - Royalty interests in partnered therapeutic candidates - Milestone payment rights from drug development programs - Commercial royalty streams on approved products - Out-licensing of legacy product candidates and technologies - Purchased receivables tied to biotech revenue streams ## Customers XOMA Royalty does not sell medicines directly to patients; it monetizes contractual rights against biotech partners and the commercial sales of partnered products. Its counterparties are pharmaceutical and biotechnology companies that license assets, pay milestones, or generate sales on products subject to royalty obligations. The business also depends on well-funded development partners that can advance clinical programs and commercialize approved therapies. - **Biotechnology license partners** (primary) — Companies that license legacy product candidates or platforms and pay upfront, annual, or milestone fees. - **Pharmaceutical commercialization partners** (primary) — Drug developers and marketers whose product sales generate royalty income for XOMA. - **Royalty financing counterparties** (secondary) — Sponsors of royalty transactions where XOMA acquires rights to future cash flows from therapeutic assets. - **Clinical-stage drug developers** (primary) — Partners advancing Phase 1-3 assets that can trigger milestone payments when development events occur. - Biotech licensees that owe milestones under out-licensing deals - Pharma partners commercializing products with royalty obligations - Developers of Phase 1-3 assets that trigger development milestones - Buyers of royalty financing capital in structured transactions - Commercial product sales channels that generate royalty-bearing revenue ## Geography XOMA Royalty is headquartered in the United States and its economic exposure is tied mainly to U.S.-listed and global biotech partners rather than to manufacturing sites. Because royalty and milestone receipts depend on where partner products are sold and developed, its revenue base is indirectly global even though the company itself is U.S.-based. The business is therefore exposed to cross-border clinical development, regulatory approvals, and product sales in multiple markets. - Headquartered in the United States - Revenue depends on partner drug sales across multiple markets - Clinical and regulatory milestones can arise in the U.S. and abroad - Royalty exposure follows where partnered products are commercialized - No disclosed country revenue split in the provided excerpts ## Strategy XOMA Royalty’s strategy is to expand a diversified portfolio of royalty and milestone assets by acquiring rights to promising therapeutic programs and commercial products. It focuses on early- to mid-stage clinical assets with meaningful commercial potential, while also adding late-stage and marketed assets that can generate nearer-term cash flows. The model depends on partner execution, so portfolio selection, diversification, and disciplined acquisition pricing are central to its competitive position. - **Expand the royalty portfolio through acquisitions** (short-term) — More assets can diversify cash flow sources and reduce dependence on any single partner or program. - **Focus on partnered clinical assets with high commercial potential** (medium-term) — Early- to mid-stage programs can create large future milestone and royalty opportunities if development succeeds. - **Maintain access to external capital for acquisitions** (short-term) — The model is acquisition-driven and requires funding to buy new royalty and milestone rights. - Acquire royalty and milestone rights across biotech assets - Target early- to mid-stage programs with commercial upside - Add late-stage and marketed assets for nearer-term cash flow - Diversify across partners, indications, and development stages - Use capital markets and structured deals to fund acquisitions ## Risks XOMA Royalty’s cash generation depends on clinical progress, regulatory approvals, and product sales by third-party partners, so timing and size of receipts can be volatile. The company also faces financing and valuation risk because it relies on external capital to fund acquisitions and because royalty assets are sensitive to partner execution, macro conditions, and market sentiment. As a biotech royalty buyer, it is exposed to development failure, commercialization setbacks, and estimation risk in valuing future cash flows. - **Partner development and commercialization risk** [high] — Milestones and royalties are only earned if third-party partners advance programs and sell products successfully. - **Financing and liquidity risk** [high] — The company may need external capital to fund acquisitions and operating needs if cash generation is insufficient. - **Valuation and forecast risk on royalty assets** [medium] — Income recognition and asset values depend on estimated future royalties and milestone timing. - **Macroeconomic and market volatility** [medium] — Interest rates, equity market conditions, and broader economic stress can affect funding access and asset pricing. - Milestone and royalty income depends on partner execution - Clinical trial or regulatory setbacks can eliminate expected cash flows - Acquisition model requires ongoing access to capital - Royalty asset values depend on sales forecasts and discount assumptions - Macro volatility can affect financing conditions and valuations ## Accounting XOMA Royalty’s reported revenue is driven by several accounting methods, including contract revenue, the EIR method, the cost recovery method, and the units-of-revenue method. Because these methods rely on estimates of future royalties, milestone timing, and partner sales, reported income can shift materially from quarter to quarter as assumptions change. Investors should also watch how purchased receivables and royalty interests are measured, since valuation judgments directly affect recognized income. - **Revenue from contracts with customers** — Can create lumpy quarterly revenue - **Effective interest rate (EIR) method** — Sensitive to forecast revisions - **Cost recovery method** — Affects timing of recognized income - **Units-of-revenue amortization** — Creates variability in reported revenue - Revenue recognition varies by contract fees, milestones, and royalty streams - EIR income depends on estimated future royalty collections - Cost recovery income reflects milestone and royalty receipts on purchased receivables - Units-of-revenue amortization changes with estimated royalties received - Fair value and cash-flow estimates can materially affect reported income --- *Last updated: 2026-04-29T05:10:52.985124+00:00*